Law360, New York (May 01, 2012, 8:15 PM ET) -- Supporters of the U.S. Food and Drug Administration got some ammo to use against potential opponents of the user fee reauthorization package Monday, when the U.S. Government Accountability Office reported that the FDA met nearly all of its drug review goals from 2000 to 2010.
GAO, in a report requested by Sens. Richard Burr, R-N.C., and Tom Coburn, R-Okla., found that the FDA met performance goals, outlined in past Prescription Drug User Fee Agreements, on review times for new drug and biologic applications.
The report could...
FDA Drug Reviews Pass Muster As User Fee Deadline Looms
To view the full article, take a free trial now.
